Haemonetics Corporation reported a net revenue of $339.4 million for the three months ended June 27, 2026, marking a 5.6% increase from $321.4 million in the same period last year. The company's gross profit also rose to $202.8 million, up 5.5% from $192.2 million, maintaining a gross margin of 59.8%. Operating income increased by 6.7% to $57.5 million, compared to $53.9 million in the prior year. However, net income saw a slight decline, falling to $33.0 million from $34.0 million, resulting in a basic earnings per share of $0.73, up from $0.71.

The company experienced notable growth in its Apheresis segment, which generated $191.3 million in revenue, a 5.3% increase from $181.7 million. This growth was driven by volume increases and market share gains in the Plasma franchise. The MedSurg segment also contributed positively, with revenues rising 6.0% to $148.1 million, supported by gains in the Hemostasis Management and Transfusion Management product lines. The organizational realignment on June 5, 2026, which combined the Plasma and Blood Center segments into Apheresis and renamed the Hospital segment to MedSurg, reflects the company's strategy to enhance operational efficiency.

In terms of operational metrics, Haemonetics reported a cash and cash equivalents balance of $223.4 million as of June 27, 2026, down from $245.4 million at the end of the previous quarter. The company’s total assets decreased to $2.37 billion from $2.40 billion, while total liabilities also saw a reduction to $1.43 billion from $1.46 billion. The company’s employee headcount remained stable, with no significant changes reported. The restructuring initiatives, including the market and regional alignment initiative, resulted in restructuring costs of $2.3 million during the quarter.

Looking ahead, Haemonetics anticipates continued growth driven by its strategic investments and product innovations. The company has allocated $31.0 million to remaining performance obligations related to contracts with a duration of one year or more, expecting to recognize approximately 70% of this amount as revenue within the next twelve months. The company remains focused on enhancing its product portfolio and operational capabilities to capture market opportunities and improve financial performance.

About HAEMONETICS CORP

Haemonetics is a global medical technology company providing blood and plasma collection, processing, and management solutions. Its core segments include Plasma, Blood Center, and Hospital, offering devices, software, and services to enhance blood and plasma collection, transfusion safety, and patient care. The company serves blood centers, plasma manufacturers, hospitals, and healthcare providers worldwide, focusing on innovation, quality, and regulatory compliance to improve healthcare outcomes.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov